Table 2.

Most common adverse events (incidence ⩾4.0% in the total population) by subgroup and in the total population.

AE	Treatment-native (N = 82)	Previously treated (N = 165)	Total (N = 247)
Any AE	46 (56.1%)	72 (43.6%)	118 (47.8%)
Flu-like symptoms	20 (24.4%)	18 (10.9%)	38 (15.4%)
MS relapse	17 (20.7%)	18 (10.9%)	35 (14.2%)
Drug ineffective	6 (7.3%)	9 (5.5%)	15 (6.1%)
Injection site erythema	7 (8.5%)	7 (4.2%)	14 (5.7%)
Fatigue	5 (6.1%)	8 (4.8%)	13 (5.3%)
Headache	6 (7.3%)	6 (3.6%)	12 (4.9%)
Skin reaction	5 (6.1%)	5 (3.0%)	10 (4.0%)
Any SAE	11 (13.4%)	6 (3.6%)	17 (6.9%)
MS relapse	7 (8.5%)	3 (1.8%)	10 (4.1%)

AE, adverse event; MS, multiple sclerosis; SAE, serious adverse event.